

HEALTHWEST

Practice Guideline

No. 12-001

Prepared By:

Effective: August 23, 1999
Revised: March 13, 2018

Cyndi Blair, RNBC
Chief Clinical Director

Approved By:

Subject: Antabuse/Campral/Naltrexone
Administration Protocol

Julia Rupp
Executive Director

I. PRACTICE GUIDELINE

Antabuse (Disulfiram), Acamprosate (Campral), Naltrexone (Revia) protocol.

II. PURPOSE

It is the commitment of HealthWest to provide quality health care that includes chronic pain management and addiction treatment for alcohol use, with patient safety as a priority.

III: APPLICATION

All HealthWest employees, volunteers, student interns, interpreters, affiliated providers, and persons under contract with HealthWest.

IV: PROTOCOL

A. Assessment

1. The objectives of the patient assessment are to determine a given patient's eligibility for treatment, to provide the basis for a treatment plan, and to establish a baseline measure for use in evaluating a patient's response to treatment.
2. The client shall undergo the following screenings and lab work prior to starting treatment:
 - a. The screening can be done by any appropriately credentialed staff member. They shall evaluate the client's alcohol problem based on a clinical assessment.

- b. A HealthWest psychiatrist or physician assistant (PA) shall evaluate for psychiatric appropriateness and capacity to use medicated assisted treatment.
- c. Releases of Information shall be obtained.
- d. Registered Nurse will collect a health history via documentation in order to collaborate care.
- e. A medical physician or PA or nurse practitioner (NP) shall conduct a physical examination.
- f. Tests shall include the following (refer to Appendix G):
 - i. Pregnancy test, if the client is capable of getting pregnant, will be administered at baseline and at provider discretion.
 - ii. Lab work shall include a Comprehensive panel, liver function tests, Hepatitis and HIV screens as well as an electrolyte baseline.
 - iii. An ECG shall be obtained at baseline if not done within the previous six months.
- g. Once the assessments and labs are complete, the psychiatrist shall decide if Disulfiram, Naltrexone, or Antabuse is appropriate.

B. Treatment and Monitoring

1. The HealthWest psychiatrist, PA/NP or nurse shall provide complete information (orally and in writing) about the medication and its effects and side effects and the client shall give informed consent (C363) to take one of the above medications.
2. The client shall be seen at least monthly for the first 90 days by a HealthWest nurse (or physician or PA) for routine monitoring, including blood pressure monitoring.
3. The client shall be seen at least quarterly by the prescribing psychiatrist or PA.
4. Liver function tests (LFTs: AST, GGT, alkaline phosphatase), cholesterol, and triglycerides, and other studies as indicated medically, shall be obtained by HealthWest staff every three months after treatment is indicated.
5. A comprehensive panel shall be run at baseline and every 6 months following treatment.
6. Disulfiram, Acamprosate, and Naltrexone use shall preferably be conducted in parallel with other ongoing substance abuse (dual diagnosis) treatment by HealthWest and/or other agencies.

- a. An individual session with their treatment team, as well as weekly group therapy is required.
- b. Participation in a peer led support group is strongly recommended.

V: REFERENCES

MDCH Medication Assisted Treatment Guidelines for Opioid Use Disorders, Corey Waller MD, MS

/ab

APPENDIX G

HEALTHWEST LABORATORY MONITORING GUIDELINES FOR USE OF PSYCHOTROPIC MEDICATIONS

Mood Stabilizers

Carbamazepine (Carbatrol, Equetro, Tegretol) and Oxcarbazepine (Trileptal)

TESTS	BASELINE	2 nd WEEK	1 st MONTH	3 rd MONTH	6 th MONTH	YEARLY
Pregnancy Test	Every 3 months for women of childbearing age					
CBC (not for Trileptal)	Yes		Yes	If indicated		Yes, or early as indicated
Liver Function Test	Yes		Yes			Yes, or early as indicated
Carbamazepine Level (Tegretol)	1 week		Yes, or early or if meds increase/decrease			Yes, or early as indicated
Kidney Function Test (BUN and Creatinine)	Yes					If indicated
TSH	Yes					If indicated
Electrolytes, especially with Trileptal (BMP)	Yes		Yes			Yes

Mood Stabilizers

Lithium (Eskalith, Lithobid, and Lithium)

TESTS	BASELINE	WEEK 1	WEEK 2	1 st MONTH	6 th MONTH	ANNUALLY
Pregnancy Test	Every 3 months for women of childbearing age					
Serum Levels		Yes	Yes, if meds increase/decrease until levels stabilize		Yes	Yes, or early if indicated
Urine Analysis	Yes					If indicated
TSH	Yes		Yes		Yes	Yes, or early if indicated
ECG*	If indicated or if 45 years or older and if pre-existing cardiac disease					If indicated
BUN/Creatinine	Yes		Yes			Yes

Mood Stabilizers

Valproic Acid (Depakene) and Divalproex Sodium (Depakote)

TESTS	BASELINE	2 WEEKS	1 MONTH	3 MONTHS	6 MONTHS	YEARLY	IF SYMPTOMS ARISE
Pregnancy	Every 3 months for women of childbearing age						Yes
CBC with Platelets	Yes	Yes			Yes	Yes	Yes
Liver Function Tests	Yes	Yes				Yes	
Electrolytes (BMP)	Yes						Yes
Drug Levels		Yes, and weekly until stabilized				Yes	Yes
Prothrombin Time							Yes
Androgens							
Amylase							Yes
Bicarb *only for Topamax	Yes		Yes				Yes

Mood Stabilizers

Lamotrigine (Lamictal)

TESTS	BASELINE	IF SYMPTOMS ARISE
Drug Level		Yes (if indicated)
Pregnancy	Every 3 months for women of childbearing age	

***Second Generation Antipsychotic**
In addition to Clozapine and Chlorpromazine

TESTS	BASELINE	8 WEEKS OR EARLY AS INDICATED	QUARTERLY	YEARLY	IF SYMPTOMS ARISE
Pregnancy	If indicated				Yes
Weight/BMI	Yes	Yes	Yes	Yes	
Waist Circumference	Yes			Yes	
Blood Pressure	Yes		Yes	Yes	Yes
Fasting Glucose/HbA1C	Yes			Yes	Yes
ECG	If indicated				Yes
Fasting Lipids Panel	Yes			Yes	
Drug Level					If indicated

*Clozapine (Clozaril): Refer to Clozapine/Clozaril Procedures. Use protocol for ANC.

ANTIDEPRESSANTS

A. SNRIs: Venlafaxine (Effexor), Duloxetine (Cymbalta)

	BASELINE	QUARTERLY
BP	Yes	Yes
Hepatic Enzyme (Duloxetine)	If indicated	If indicated

B. MAOIs

	BASELINE	QUARTERLY	YEARLY
Liver Enzymes	Yes		Yearly
BP	Yes		Yearly

C. Tricyclics

	BASELINE	YEARLY
Pregnancy Test	If indicated	
ECG	If indicated	If indicated
Drug Level		If indicated
Liver Function Test		If indicated

D. Serotonin: 2 Antagonist/Reuptake Inhibitors: Nefazodone (Serzone)

	BASELINE	YEARLY
Liver Function Test	Yes	Yes, or earlier if indicated

Medication Assisted Treatment

Vivitrol (Vivitrol Injection)

TESTS	BASELINE	2 nd WEEK	1 st MONTH	3 rd MONTH	6 th MONTH	YEARLY
Pregnancy Test	Yes And at provider discretion					
Liver Function Test	Yes			Yes	Yes	Yes, every three months throughout treatment
Drug Screen	Yes					To be done prior to each injection.

Campral (Acamprosate)

TESTS	BASELINE	2 nd WEEK	1 st MONTH	3 rd MONTH	6 th MONTH	YEARLY
Pregnancy Test	Yes And at provider discretion					
Kidney Function Test (BUN/Creatinine)	Yes				Yes	Yes, every six months throughout treatment
Electrolytes	Yes				Yes	Yes, every six months throughout treatment

Revia, Antabuse (Naltrexone, Disulfiram)

TESTS	BASELINE	2 nd WEEK	1 st MONTH	3 rd MONTH	6 th MONTH	YEARLY
Pregnancy Test	Yes And at provider discretion					
Liver Function Test	Yes			Yes	Yes	Yes, every three months throughout treatment
ECG	Yes if not done in the last 6 months					
Hepatitis Screen	Yes					
HIV	Yes					
Electrolytes	Yes				Yes	Yes, every six months throughout treatment

Suboxone
(Buprenorphine, Naloxone)

TESTS	BASELINE	2 nd WEEK	1 st MONTH	3 rd MONTH	6 th MONTH	YEARLY
Pregnancy Test	Yes And at provider discretion					
Liver Function Test	Yes			Yes	Yes	Yes, every three months throughout treatment
Kidney Function Test (BUN/Creatinine)	Yes					
Electrolytes	Yes					
Hepatitis Screen	Yes					
HIV Screen	Yes					

HEALTHWEST

MEDICATION ASSISTED TREATMENT AGREEMENT

Date: _____ Name: _____ Case Number: _____

As a participant receiving medication assisted treatment for a substance use disorder, I freely and voluntarily agree to accept this treatment agreement/contract as follows:

1. I agree to keep, and be on time to, all my scheduled appointments with my physician and/or physician assistant/nurse practitioner.
2. I agree to not sell, share, or give any of my medication to another individual.
3. I agree that my medication will be provided at scheduled appointments; missed appointments may result in a delay in receiving medication. Medication will be provided to take home in quantities based on individual assessment. Random call-backs to verify count will occur. I will respond to call-backs within 24 hours.
4. I agree that the medication I receive is my responsibility and that I will keep it in a safe, secure place. I agree that lost medication will not be replaced regardless of the reasons for such loss.
5. I agree to not obtain medications from any physicians, pharmacies, or other sources without informing my treating physician. I understand that mixing buprenorphine with other medications, especially benzodiazepines such as valium, alcohol, and other drugs of abuse can be dangerous and even deadly.
6. I agree to take my medication as prescribed, inclusive of all prescribed medications, and will not alter the way I take my medication without consulting with my doctor first.
7. Urine, Saliva, and Serum Drug Screens will be completed on a regular and random basis; visual observation by staff may be required.
8. I understand that medication alone is not sufficient treatment for my disease, and I agree to participate in the recommended treatment program to assist in my treatment. The recommended treatment program consists of the following:

Week 1 – 4:

- Weekly Medication Review
- Weekly individual session with member of the multidisciplinary treatment team for MAT monitoring
- Weekly Drug Screen
- Weekly Group Therapy

Week 5 – 12:

- Weekly Individual session with treatment team
- Weekly Drug Screen
- Weekly Group Therapy
- Monthly Medication Review at a minimum or as determined by the provider.

Week 13/Month 4 – Month 6:

- Month Medication Review or as determined by the provider.
- Monthly Drug screen or as determined by the provider.
- Combination of Group and Individual sessions at least one time per week

Month 7 and on:

- Medication review 1 – 3 times every 90 days
- Drug screen 1 – 3 times every 90 days
- Group and Individual sessions as recommended within Person Centered Plan

Instances of positive drug screens (or negative for Suboxone) will include increased support with return to weekly reviews, therapy, and drug screens for a period of time as determined with my treatment team.

Consumer Signature

Date

Treatment Team Member Signature

Date